CStone Pharmaceuticals CSPHF Stock
CStone Pharmaceuticals Price Chart
CStone Pharmaceuticals CSPHF Financial and Trading Overview
| CStone Pharmaceuticals stock price | 0.6 USD |
| Previous Close | 0.6 USD |
| Open | 0.7 USD |
| Bid | 0.56 USD x 200000 |
| Ask | 0.64 USD x 10000 |
| Day's Range | 0.68 - 0.7 USD |
| 52 Week Range | 0.52 - 1.01 USD |
| Volume | 4K USD |
| Avg. Volume | 3.59K USD |
| Market Cap | 1.11B USD |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CSPHF Valuation Measures
| Enterprise Value | 262.28M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.112961 |
| Price/Book (mrq) | 11.257367 |
| Enterprise Value/Revenue | 0.973 |
| Enterprise Value/EBITDA | -0.649 |
Trading Information
CStone Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.19 |
| 52-Week Change | 14.86% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 1.01 USD |
| 52 Week Low | 0.52 USD |
| 50-Day Moving Average | 0.91 USD |
| 200-Day Moving Average | 0.88 USD |
CSPHF Share Statistics
| Avg. Volume (3 month) | 3.59K USD |
| Avg. Daily Volume (10-Days) | 16.44K USD |
| Shares Outstanding | 1.6B |
| Float | 1.1B |
| Short Ratio | N/A |
| % Held by Insiders | 22.23% |
| % Held by Institutions | 15.61% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -162.10% |
| Operating Margin (ttm) | -62.99% |
| Gross Margin | 19.00% |
| EBITDA Margin | -149.80% |
Management Effectiveness
| Return on Assets (ttm) | -18.88% |
| Return on Equity (ttm) | -89.12% |
Income Statement
| Revenue (ttm) | 269.58M USD |
| Revenue Per Share (ttm) | 0.19 USD |
| Quarterly Revenue Growth (yoy) | 43.79% |
| Gross Profit (ttm) | 51.25M USD |
| EBITDA | -403846016 USD |
| Net Income Avi to Common (ttm) | -437003008 USD |
| Diluted EPS (ttm) | -0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 962.49M USD |
| Total Cash Per Share (mrq) | 0.65 USD |
| Total Debt (mrq) | 348.52M USD |
| Total Debt/Equity (mrq) | 56.51 USD |
| Current Ratio (mrq) | 2.182 |
| Book Value Per Share (mrq) | 0.061737347 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -327747008 USD |
| Levered Free Cash Flow (ttm) | -251060624 USD |
Profile of CStone Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | C1 Building |
| ZIP | 215123 |
| Phone | 86 512 8718 6550 |
| Website | https://www.cstonepharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 136 |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Q&A For CStone Pharmaceuticals Stock
What is a current CSPHF stock price?
CStone Pharmaceuticals CSPHF stock price today per share is 0.6 USD.
How to purchase CStone Pharmaceuticals stock?
You can buy CSPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CStone Pharmaceuticals?
The stock symbol or ticker of CStone Pharmaceuticals is CSPHF.
Which industry does the CStone Pharmaceuticals company belong to?
The CStone Pharmaceuticals industry is Biotechnology.
How many shares does CStone Pharmaceuticals have in circulation?
The max supply of CStone Pharmaceuticals shares is 1.6B.
What is CStone Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
CStone Pharmaceuticals PE Ratio is now.
What was CStone Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
CStone Pharmaceuticals EPS is -0.05 USD over the trailing 12 months.
Which sector does the CStone Pharmaceuticals company belong to?
The CStone Pharmaceuticals sector is Healthcare.